Calliditas Therapeutics AB (publ)
CALT
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -62.86% | -28.37% | -2.37% | 36.76% | 57.28% |
| Total Depreciation and Amortization | 29.45% | 29.45% | 29.45% | 65.29% | 65.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,262.33% | 523.37% | 4,372.85% | 689.78% | -62.46% |
| Change in Net Operating Assets | 155.09% | -226.19% | -194.58% | 309.22% | 29.46% |
| Cash from Operations | 16.72% | -7.66% | -22.32% | 70.05% | 57.16% |
| Capital Expenditure | -412.88% | -412.88% | -412.88% | 68.49% | 68.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 76.57% | 36.70% | 70.26% | -301.45% | -98.81% |
| Cash from Investing | -114.46% | -168.32% | -147.86% | -22.08% | 35.28% |
| Total Debt Issued | 277.18% | 95.81% | 95.81% | 7.96% | -41.45% |
| Total Debt Repaid | -6,384.63% | -6,664.70% | -7,561.08% | -30.02% | -35.90% |
| Issuance of Common Stock | -99.96% | -- | -- | -50.73% | -91.88% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,009.83% | -2,009.83% | -2,008.16% | 96.77% | 98.29% |
| Cash from Financing | -27.89% | -62.83% | -66.82% | 0.10% | -68.84% |
| Foreign Exchange rate Adjustments | -112.56% | -50.88% | -173.61% | -47.32% | 142.18% |
| Miscellaneous Cash Flow Adjustments | -200.00% | -200.00% | -150.00% | 0.00% | 0.00% |
| Net Change in Cash | -901.79% | -214.54% | -202.72% | 108.73% | -95.15% |
